• Aliases: BIBF1120, Vargatef (planned trade name)
    • A triple angiokinase inhibitor of VEGFR 1-3, PDGFR-α and -β, and FGFR 1-3
    • Currently under investigation in phase 3 clinical trials in advanced NSCLC ovarian cancer and HCC.
    • Recommended phase 3 dose: 200 mg twice daily
    • Half-life: 13 to 19 hours
    • Common side effects: Diarrhea, nausea/vomiting, anorexia, liver dysfunction (hyperbilirubinemia, transaminitis), increased amylase/lipase, hypertension
    (Mross et al., 2010)
    Other topics in Targeted and Immunotherapy Agents